PharmaBoardroom today releases its new 53 page Hungary Healthcare & Life Sciences Review 2016.
This report offers companies, investors, policymakers, and stakeholders crucial insight into Hungary; a country with more than 100 years of history in pharmaceuticals and a leading regional role in the industry. Regulatory reform post-2008 has seen Hungary weather the storm of economic recession and re-establish itself as a hub for world-class R&D, with a concentration of pharma MNCs, a growing number of biotech SMEs, innovative research institutions, and a highly skilled and affordable workforce.
The report features in-depth exclusive interviews with leading figures from public institutions and private companies, comprehensive articles, and up-to-date facts and figures on the Hungarian healthcare and pharma sectors.
Features
Featured topics include:
- Health literacy and preventative healthcare
- Domestic manufacturing
- Homegrown talent
- Hungary’s pharmaceutical legacy
- Regulatory reform
- Financing innovation
Interviews
The report features in-depth interviews with:
- Péter Szijjártó, Minister of Foreign Affairs and Trade
- Dr. Lívia Ilku, MAGYOSZ
- Dr. Judit Bidló, OEP
- Dr. Zoltán Ács and Dr. Dávid Greskovits, Meditop
- Dr. Jan Frederic Kesselhut, Servier
- Zsolt Szepesházi, IMS Health
- Anita Ordog, Angelini
- Anna Wienner, IBSA
Quotes
- “The fact that after 2010 Hungary could become a production center in Europe means Hungary has achieved its first goal, but of course there are additional plans. Therefore, efforts should be made in the future and the first steps have already been taken for this to make Hungary also Europe’s center of innovation”
Péter Szijjártó, Minister of Foreign Affairs and Trade
- “From a drug reimbursement point of view, we have one of the most complex and comprehensive regulatory frameworks in Europe, which aims to cover all medical and medicinal needs for society—even when it comes to hospital and outpatient care”
Dr. Judit Bidló, OEP
- “We’re actually right now on the cusp of establishing a strategic agreement with the government, that if successful, will enshrine the government’ s commitment to the proper development of this industry”
Dr. Lívia Ilku, MAGYOSZ
- “Speaking specifically about the medical needs, there are, of course, more globally pervasive disease segments such as cardiovascular and diabetes present, but what has been truly notable in Hungary is the rate of cancer mortality—which is exceedingly high when compared to other OECD countries”
Dr. Jan Frederic Kesselhut, Servier
Click here to register for free and download the report.
